台康生技股份有限公司 Approved
最後更新時間 2025/06/03 , 08:17 AM
最後更新時間 2025/06/03 , 08:17 AM
負責人
Liu,Li-Cheng
統一編號
54150737
成立日期
2012/12/21
資本額
NT$4,000,000,000
實收資本額
NT$3,062,161,660
股票代號
6589
電話
02-77080123
地址
No. 101, Ln. 169, Kangning St., Xizhi Dist., New Taipei City, 221, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Liu,Li-Cheng Chairman 0.83%
Cheng,Zheng-Yu Director 6.06% Formosa Laboratories, Inc.
Chen,Tou-Hui Director 4.99% EXECUTIVE YUAN NATIONAL DEVELOPMENT FUND MANAGEMENT COUNCIL
MANAGEMENT COMMITTEE OF YAOHUA GLASS CO., LTD. Director 4.27%
Lv,Jun-Fu Director 8.98% FOXCONN TECHNOLOGY CO., LTD.
Chen,Yu-Ting Director 8.98% FOXCONN TECHNOLOGY CO., LTD.
Chen,Bo-Zhi Independent Director 0.00%
Chen,Ming-Xian Independent Director 0.00%
Yin,Fu-Xiu Independent Director 0.00%
Zhang,Ming-Chao Independent Director 0.00%
營業項目
  • Manufacture of Drugs and Medicines(200211)
  • Retail Sale of Pharmaceutical and Medical Goods in Specialized Stores(475112)
  • Management Consultancy Activities(702099)
  • Other Professional, Scientific and Technical Activities Not Elsewhere Classified(760999)
  • 公司歷程
  • Change Person in Charge to Liu,Li-Cheng
    2022/07/06
  • Change Capital to 4,000,000,000
    2021/08/27
  • Change Capital to 3,000,000,000
    2019/12/06
  • Change Capital to 2,000,000,000
    2018/04/20
  • Change Capital to 1,200,000,000
    2015/01/30
  • Change Person in Charge to Li,Zhong-He
    2013/10/21
  • Change Capital to 540,000,000
    2013/06/17
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 181,923 1,008,960 1,022,653
    Operating cost 164,763 789,975 785,912
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 17,160 218,985 236,741
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 17,160 218,985 236,741
    Operating expenses 239,980 1,172,786 1,268,718
    Other gain (loss), net - - -
    Operating profit (loss) -222,820 -953,801 -1,031,977
    Non-operating income and expenses 66,083 257,296 118,327
    Net profit (loss) before tax -156,737 -696,505 -913,650
    Income tax expense (benefits) 357 1,839 1,558
    Net profit (loss) of ongoing business for the current period -157,094 -698,344 -915,208
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -157,094 -698,344 -915,208
    Other comprehensive profit (loss), net -13,080 -92,762 46,118
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -170,174 -791,106 -869,090
    Net profit (loss) attributable to owners of parent company -157,094 -698,344 -915,208
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company -170,174 -791,106 -869,090
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 -2 -3
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -111,754 -311,443 -848,556
    Net cash inflows (outflows) from investing activities -71,031 -1,015,048 -219,018
    Net cash inflow (outflow) from financing activities -123,172 370,890 -6,820
    Effect of Exchange Rate Changes on Cash and Cash Equivalents 1,164 2 692
    Increase (decrease) in cash and cash equivalents in the current period -304,793 -955,599 -1,073,702
    Beginning balance of cash and cash equivalents 4,097,584 5,053,183 6,126,885
    Ending balance of cash and cash equivalents 3,792,791 4,097,584 5,053,183
    項目 2025 2024 2023
    Current asset 5,227,534 5,952,002 6,915,506
    Non-current asset 5,540,324 4,924,414 4,247,053
    Total asset 10,767,858 10,876,416 11,162,559
    Current liability 702,755 947,370 707,165
    Non-current liability 1,214,328 670,789 437,931
    Total liability 1,917,083 1,618,159 1,145,096
    share capital 3,063,381 3,062,492 3,060,516
    Equity - secruity token - - -
    capital reserve 6,959,252 6,954,889 7,830,216
    retained earning -855,438 -698,344 -915,208
    Other equity -10,955 230 41,939
    Treasury stock -305,465 -61,010 -
    Total equity attributable to owners of parent company 8,850,775 9,258,257 10,017,463
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 8,850,775 9,258,257 10,017,463
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 122,000 33,000 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 4,000,000 841,000 0
    Net asset value per share 29 30 32
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額 0
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額 0
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    2024 01-03 0~0.5M 1~2M
    2023 01-12 1~2M 4~5M
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    請下載完整報告 請下載完整報告 請下載完整報告 請下載完整報告
    商標
  • EirGenix
  • EirGenix
  • 益康平
  • EIRGASUN
  • EirGenix & Device
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    飛確新型冠狀病毒抗原快速檢驗試劑壹批 國立成功大學 110/07/20 840000.0
    COVID-19抗原快速檢測試劑緊急採購案 臺中市政府衛生局 110/07/02 1850000.0
    新型新冠病毒抗原快速檢驗試劑採購案 新北市政府衛生局 110/05/26 4500000.0
    110年度新型冠狀病毒快速檢測試劑 屏東縣檢驗中心 110/05/20 1864800.0
    候選疫苗之產程開發與先導製程最適化委託服務-細胞庫生產及特性驗證分析 財團法人國家衛生研究院 109/07/29 4500000.0
    人類IL12p80蛋白質(人類IL12p40同二聚體) 財團法人國家衛生研究院 106/07/04 1370000.0
    裁判書查詢
  • Compensation for damage, etc.
    2015
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。